Moderate-to-severe dry eye disease may be effectively treated with a water-free cyclosporine solution, 0.1%, according to a Johns Hopkins University study funded by Novaliq.
Published in ,1 834 participants were randomly assigned to twice-daily cyclosporine solution or vehicle for 29 days.
Participants treated with cyclosporine solution had greater improvement in total corneal fluorescein staining (tCFS) than the vehicle group (−4.0 versus −3.6 grades) at day 29 (change [Δ], −0.4; 95% confidence interval [CI], −0.8 to 0; P = 0.03). Treatment benefits in the dryness score from baseline were seen in both groups: −12.2 points for cyclosporine and −13.6 points for vehicle (Δ = 1.4; 95% CI, −1.8 to 4.6; P = 0.38).
Clinically meaningful reductions of three grades or higher in Tcfs were achieved by 71.6% in the cyclosporine group versus 59.7% in the vehicle group (Δ = 12.%; 95% CI, 6.0 to 19.3%; P < 0.001).
Compared with non-responders, responders showed greater improvement in symptoms at day 29, including dryness (Δ = −4.6; 95% CI, −8.0 to −1.2; P = 0.007) and blurred vision (Δ = −3.5; 95% CI, −6.6 to −4.0; P = 0.03).
Reference
Esen K. Akpek et al, Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease, JAMA Ophthalmology (2023). DOI: 10.1001/jamaophthalmol.2023.0709
